Communiqués Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2026			Pré-ouverture 14:48:18
676,69 ^USD	-0,33%		696,38	+2,91%

16/07	Merck obtient le feu vert de la FDA pour le premier traitement oral de sa catégorie contre le cholestérol	RE
15/07	Alnylam lance une étude de phase intermédiaire sur le mivelsiran dans la maladie d'Alzheimer associée au syndrome de Down	MT

Communiqués

18/07	REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026	NE
16/07	Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit	BU
25/06	Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast	GL
22/06	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)	GL
04/06	Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO	GL
28/05	Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak	GL
25/05	Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)	NE
22/05	Regeneron Pharmaceuticals - Lynozyfic Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis	AQ
22/05	Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss	GL
21/05	Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis	GL
20/05	REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud	BU
18/05	UPDATE - Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair	AQ
18/05	Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas	GL
16/05	Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma	GL
15/05	Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair	GL
08/05	Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years	GL
08/05	Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years	AQ
05/05	Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial	GL
01/05	Regeneron Pharmaceuticals : Q1 2026 Earnings Conference Call Transcript	PU
29/04	Regeneron Pharmaceuticals : REGN April 2026 Corporate Presentation	PU
29/04	Regeneron: Q1 Earnings Snapshot	AQ
29/04	Regeneron Reports First Quarter 2026 Financial and Operating Results	GL
23/04	Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.	GL
23/04	Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.	GL
22/04	Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)	GL